Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC
Clinical trial NCT05215951 · TERMINATED
Trial details
- NCT number
- NCT05215951
- Sponsor
- AstraZeneca
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-19
- Primary completion
- 2023-03-09
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.